4.7 Article

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy

期刊

GENES & DEVELOPMENT
卷 29, 期 18, 页码 1891-1896

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.261867.115

关键词

DNA damage repair; ERCC5; protein synthesis; uORF

资金

  1. Cancer Research UK
  2. Biotechnology and Biological Sciences Research Council
  3. Medical Research Council
  4. Societe Francaise des Cancers de l'Enfant/Enfants et Sante
  5. Etoile de Martin
  6. Fondation Carrefour
  7. Joe Foote Foundation
  8. BBSRC [BB/F02326X/2] Funding Source: UKRI
  9. MRC [MC_EX_G0902052, MC_UP_A600_1023, MC_UP_A600_1024] Funding Source: UKRI
  10. Biotechnology and Biological Sciences Research Council [BB/F02326X/2] Funding Source: researchfish
  11. Medical Research Council [MC_UP_A600_1023, MC_EX_G0902052, MC_UP_A600_1024] Funding Source: researchfish

向作者/读者索取更多资源

We show that a common polymorphic variant in the ERCC5 5' untranslated region (UTR) generates an upstream ORF (uORF) that affects both the background expression of this protein and its ability to be synthesized following exposure to agents that cause bulky adduct DNA damage. Individuals that harbor uORF1 have a marked resistance to platinum-based agents, illustrated by the significantly reduced progression-free survival of pediatric ependymoma patients treated with such compounds. Importantly, inhibition of DNA-PKcs restores sensitivity to platinum-based compounds by preventing uORF1-dependent ERCC5 expression. Our data support a model in which a heritable 5' noncoding mRNA element influences individuals' responses to platinum-based chemotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据